Vergleich

Fluoxetine (hydrochloride) Europäischer Partner

ArtNr HY-B0102A-500mg
Hersteller MedChem Express
CAS-Nr. 56296-78-7
Menge 500 mg
Quantity options 100 mg 10 mM/1 mL 10 mg 500 mg 50 mg 5 mg
Kategorie
Typ Inhibitors
Specific against other
Purity 99.97
Citations [1]Malberg JE, et al. Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. Neuropsychopharmacology. 2003 Sep;28(9):1562-71|[2]Kodama M, et al. Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol Psychiatry. 2004 Oct 15;56(8):570-80.|[3]Wang JW, et al. Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. J Neurosci. 2008 Feb 6;28(6):1374-84.|[4]Bymaster FP, et al. Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl). 2002 Apr;160(4):353-61|[5]Zhang W, et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology. 2000 Sep;23(3):250-62.|[6]Su WJ, et al. Antidiabetic drug glyburide modulates depressive-like behavior comorbid with insulin resistance. J Neuroinflammation. 2017 Oct 30;14(1):210.
Fundam Clin Pharmacol. 2018 Aug;32(4):363-377.|J Neuroinflammation. 2017 Oct 30;14(1):210.|J Neuroinflammation. 2023 May 10;20(1):112.|Neuropharmacology. 2021 Feb 15;184:108410.|Neurotox Res. 2020 Dec;38(4):887-899.|Preprints. 2023 Dec 27.|World J Biol Psychiatry. 2024 Nov 29:1-18.|Behav Brain Res. 2017 Jan 15;317:62-70. |Behav Pharmacol. 2021 Jan 6.|Behav Pharmacol. 2024 Apr 24.|Behav Pharmacol. 2024 Dec 2.|Biochem Biophys Res Commun. 2020 Feb 19;522(4):862-868.|Biochem Pharmacol. 2023 Oct 5:115846.|Biomedicines. 2023 Apr 26, 11(5), 1279.|Brain Behav Immun. 2021 Mar 15;S0889-1591(21)00114-8.|Cell Prolif. 2021 Jan;54(1):e12953.|Cell Rep. 2021 Nov 2;37(5):109957.|Chemosphere. 2019 Jun;225:378-387. |Eur J Pharmacol. 2019 Jan 15;843:260-267.|J Clin Psychopharmacol. 2021 Jun 11.|J Psychiatr Res. 2023 Oct 19.|J Transl Med. 2024 Aug 22;22(1):785.|Nat Med. 2019 Sep;25(9):1428-1441.|Orebro University. 2024.|Prog Neuropsychopharmacol Biol Psychiatry. 2017 Jun 15;79(Pt B):258-267.|Reprod Toxicol. 2025 Jan 16:108840.|Research Square Preprint. 2023 Jun 16.|Research Square Preprint. 2023 Jun 29.|Research Square Preprint. 2024 Dec 16.|Virol J. 2024 Aug 8;21(1):181.
Smiles FC(C1=CC=C(OC(C2=CC=CC=C2)CCNC)C=C1)(F)F.Cl
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Alias LY 110140
Versandbedingung Raumtemperatur
Lieferbar
Manufacturer - Type
Reference compound
Manufacturer - Applications
Cancer-programmed cell death
Manufacturer - Targets
Autophagy; Serotonin Transporter
Shipping Temperature
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Molecular Weight
345.79
Product Description
Fluoxetine hydrochloride (LY 110140) is an antidepressant and a selective serotonin reuptake inhibitor.
Manufacturer - Research Area
Neurological Disease; Cancer
Solubility
DMSO: ≥ 25 mg/mL|H2O: 8.33 mg/mL (ultrasonic)
Manufacturer - Pathway
Autophagy; Neuronal Signaling
Biological activity
Fluoxetine hydrochloride (LY 110140) is an antidepressant and a selective serotonin reuptake inhibitor.
In Vitro: Fluoxetine hydrochloride (LY 110140) blocks the downregulation of cell proliferation resulting from inescapable shock (IS) of hippocampal cell[1].?Fluoxetine increases the number of newborn cells in the dentate gyrus of the hippocampus of adult rat. Fluoxetine also increases the number of proliferating cells in the prelimbic cortex[2].?Fluoxetine accelerates the maturation of immature neurons. Fluoxetine enhances neurogenesis-dependent long-term potentiation (LTP) in the dentate gyrus[3].?Fluoxetine, but not citalopram, fluvoxamine, paroxetine and sertraline, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Fluoxetine produces robust and sustained increases in extracellular concentrations of norepinephrine and dopamine after acute systemic administration[4].
In Vivo: Fluoxetine hydrochloride (LY 110140) treatment also reverses the deficit in escape latency observed in animals exposed to inescapable shock in adult male Sprague-Dawley rats[1]. Fluoxetine (5 mg/kg) alone increases cell proliferation in the dentate gyrus. Coadministration (fluoxetine 5 mg/kg + olanzapine) also significantly increases the number of BrdU-positive cells compared with the control group[2]. Fluoxetine combined with Olanzapine produces robust, sustained increases of extracellular levels of dopamine ([DA](ex)) and norepinephrine ([NE](ex)) up to 361% and 272% of the baseline, respectively, which are significantly greater than either drug alone[5].
Clinical information
Launched

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Menge: 500 mg
Lieferbar: In stock
lieferbar

Vergleichen

Auf den Wunschzettel

Angebot anfordern

Lieferzeit anfragen

Technische Frage stellen

Bulk-Anfrage stellen

Fragen zum Produkt?
 
Schließen